|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/04/22 Biodesix Inc. 10-Q 6/30/22 75:13M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 2.79M
2: EX-10.1 Material Contract HTML 46K
3: EX-10.2 Material Contract HTML 24K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 28K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 28K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 24K
13: R1 Document and Entity Information HTML 78K
14: R2 Condensed Balance Sheets HTML 152K
15: R3 Condensed Balance Sheets (Parenthetical) HTML 42K
16: R4 Condensed Statements of Operations HTML 78K
17: R5 Condensed Statements of Stockholders' Equity HTML 82K
18: R6 Condensed Statements of Cash Flows HTML 131K
19: R7 Organization and Description of Business HTML 40K
20: R8 Summary of Significant Accounting Policies HTML 58K
21: R9 Recently Issued Accounting Standards HTML 48K
22: R10 Fair Value HTML 112K
23: R11 Supplementary Balance Sheet Information HTML 176K
24: R12 Debt HTML 124K
25: R13 Leases HTML 90K
26: R14 Equity HTML 1.10M
27: R15 Share-Based Compensation HTML 194K
28: R16 Net Loss per Common Share HTML 122K
29: R17 Income Taxes HTML 28K
30: R18 Commitments and Contingencies HTML 44K
31: R19 Summary of Significant Accounting Policies HTML 87K
(Policies)
32: R20 Fair Value (Tables) HTML 92K
33: R21 Supplementary Balance Sheet Information (Tables) HTML 177K
34: R22 Debt (Tables) HTML 76K
35: R23 Leases (Tables) HTML 67K
36: R24 Revenue and Accounts Receivable Credit HTML 102K
Concentration (Tables)
37: R25 Share-Based Compensation (Tables) HTML 190K
38: R26 Net Loss per Common Share (Tables) HTML 119K
39: R27 Organization and Description of Business - HTML 26K
Additional Information (Details)
40: R28 Summary of Significant Accounting Policies - HTML 54K
Additional Information (Details)
41: R29 Recently issued Accounting Standards - Additional HTML 34K
Information (Details)
42: R30 Fair Value - Summary of Fair Value of Outstanding HTML 30K
Borrowings (Details)
43: R31 Fair Value - Schedule of Reported Fair values of HTML 30K
Contingent Consideration (Details)
44: R32 Fair Value - Schedule of Changes in Contingent HTML 39K
Consideration (Details)
45: R33 Fair Value - Additional Information (Details) HTML 102K
46: R34 Supplementary Balance Sheet Information - Property HTML 45K
and Equipment (Details)
47: R35 Supplementary Balance Sheet Information - HTML 27K
Additional Information (Details)
48: R36 Supplementary Balance Sheet Information - HTML 46K
Intangible Assets, Excluding Goodwill (Details)
49: R37 Supplementary Balance Sheet Information - Schedule HTML 37K
of Amortization Related to Remaining Net
Intangible Assets Schedule to Amortize (Details)
50: R38 Supplementary Balance Sheet Information - Accrued HTML 30K
Liabilities (Details)
51: R39 Debt - Summary of Long-term Notes Payable HTML 41K
(Details)
52: R40 Debt - Additional Information (Details) HTML 200K
53: R41 Debt - Scheduled Principal Repayments (Maturities) HTML 39K
of Long-term Obligations (Details)
54: R42 Leases - Additional Information (Details) HTML 101K
55: R43 Leases - Summary of Future Minimum Lease Payments HTML 41K
for Operating Leases (Details)
56: R44 Leases - Summary of Future Minimum Lease Payments HTML 23K
for Operating Leases (Parenthetical) (Details)
57: R45 Leases - Summary of Future Minimum Lease Payments HTML 38K
Which Do Not Include Amounts for Common Area
Maintenance, Insurance, Or Taxes, for Operating
Lease Obligations (Details)
58: R46 Equity - Additional Information (Details) HTML 114K
59: R47 Revenue and Accounts Receivable Credit HTML 45K
Concentration - Additional Information (Details)
60: R48 Revenue and Accounts Receivable Credit HTML 35K
Concentration - Summary of Revenue (Details)
61: R49 Revenue and Accounts Receivable Credit HTML 44K
Concentration - Summary of Revenue and Accounts
Receivable by Third-party Payors and Other
Customers (Details)
62: R50 Share-Based Compensation - Additional Information HTML 48K
(Details)
63: R51 Share-Based Compensation - Summary of Pre-tax HTML 32K
Share-based Compensation Expense (Details)
64: R52 Share-Based Compensation - Summary of Stock Option HTML 65K
Activity (Details)
65: R53 Share-Based Compensation - Summary of Restricted HTML 46K
Stock Units Activity (Details)
66: R54 Net Loss per Common Share - Additional Information HTML 38K
(Details)
67: R55 Net Loss per Common Share - Schedule of HTML 40K
Computation of Basic and Diluted Loss per Share
Attributable to Stockholders (Details)
68: R56 Net Loss per Common Share - Schedule of Common HTML 35K
Stock Equivalents Excluded from Diluted Net Loss
Attributable to Common Stockholders (Details)
69: R57 Income Taxes - Additional Information (Details) HTML 28K
70: R58 Commitments and Contingencies - Additional HTML 75K
Information (Details)
73: XML IDEA XML File -- Filing Summary XML 132K
71: XML XBRL Instance -- bdsx-20220630_htm XML 3.54M
72: EXCEL IDEA Workbook of Financial Reports XLSX 169K
9: EX-101.CAL XBRL Calculations -- bdsx-20220630_cal XML 167K
11: EX-101.DEF XBRL Definitions -- bdsx-20220630_def XML 909K
8: EX-101.LAB XBRL Labels -- bdsx-20220630_lab XML 1.75M
12: EX-101.PRE XBRL Presentations -- bdsx-20220630_pre XML 1.27M
10: EX-101.SCH XBRL Schema -- bdsx-20220630 XSD 236K
74: JSON XBRL Instance as JSON Data -- MetaLinks 471± 760K
75: ZIP XBRL Zipped Folder -- 0000950170-22-014433-xbrl Zip 408K
| EX-10.2 |
Exhibit 10.2
Amendment Number One
To The
Biodesix, Inc.
2021 Senior Management Bonus to Equity Plan
Whereas, Biodesix, Inc., a Delaware corporation (the “Company”) heretofore has adopted and maintains the Biodesix, Inc. 2021 Senior Management Bonus to Equity Plan (the “Plan”), a subplan of the Biodesix, Inc. 2020 Equity Incentive Plan (the “Equity Incentive Plan”) to provide certain designated employees of the Company or its subsidiaries with the opportunity to receive a portion of their annual cash bonus in the form of a Nonstatutory Stock Option (as defined under the Equity Incentive Plan);
Whereas, the Board of Directors of the Company (the “Board”) may amend the Plan at any time; and
Whereas, the Board desires to amend the Plan to provide for the cancellation of elections thereunder in the event the Company enters into, or announces its intention to enter into, an agreement that, if consummated, would constitute a Change in Control (as defined under the Equity Incentive Plan).
Now, therefore, be it Resolved, that the Plan hereby is amended, effective for Option Elections (as defined in the Plan) in respect of Bonus Year 2022 and subsequent Bonus Years, to insert a new Section 5(e), to read as follows:
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/23/24 Biodesix Inc. S-1 4:2.3M Donnelley … Solutions/FA 3/01/24 Biodesix Inc. 10-K 12/31/23 85:12M Donnelley … Solutions/FA 3/06/23 Biodesix Inc. 10-K 12/31/22 87:15M Donnelley … Solutions/FA 2/02/23 Biodesix Inc. S-8 2/02/23 4:77K Donnelley … Solutions/FA 11/18/22 Biodesix Inc. 424B5 1:492K Donnelley … Solutions/FA 11/16/22 Biodesix Inc. 424B5 1:495K Donnelley … Solutions/FA |